World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT01190982
Date of registration: 26/08/2010
Primary sponsor: Insys Therapeutics Inc
Public title: Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer
Scientific title: A Multicenter, Open-Label, Phase II Study of LEP-ETU for Efficacy and Safety in Patients With Metastatic Breast Cancer
Date of first enrolment: March 2008
Target sample size: 70
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT01190982
Study type:  Interventional
Study design:  Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment  
Countries of recruitment
India
Contacts
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Be 18 years or older and female.

2. Have histologically or cytologically confirmed diagnosis of invasive adenocarcinoma
originating in the breast.

3. Have at least one target lesion per RECIST criteria

4. If the patient has received adjuvant or neoadjuvant taxane therapy, the patient must
not have relapsed with breast cancer within one year of completing this therapy.

5. Have received prior chemotherapy in the adjuvant or metastatic setting with an
anthracycline unless contraindicated.

6. Have no other malignancy within the past five years, except non-melanoma skin cancer,
cervical intraepithelial neoplasia (CIN), or in-situ cervical cancer (CIS).

7. Have the following hematology levels at Baseline:

- ANC greater than or equal to 1,500 x 106 cells/L;

- Platelets greater than or equal to 100 x 109 cells/L;

- Hgb greater than or equal to 90 g/L.

8. Have the following chemistry levels at Baseline:

- AST (SGOT), ALT (SGPT) less than or equal to 2.5 x ULN if no evidence of liver
metastases;

- AST (SGOT), ALT (SGPT) less than or equal to 5 x ULN if liver metastases are
present;

- Total bilirubin less than or equal to 26 micromol/L (1.5 mg/dL);

- Creatinine less than or equal to 177 micromol/L (2 mg/dL); or 24-hour

- Alkaline phosphatase less than or equal to 5 x ULN (unless bone metastasis is
present in the absence of liver metastasis).

9. Have a life expectancy of greater than or equal to 12 weeks.

10. Have an ECOG Performance status of 0-2.

11. Patients of child-bearing potential must agree to use acceptable contraceptive
methods (e.g., double barrier) during treatment.

12. Patient or legal representative must understand the investigational nature of this
study and sign an Independent Ethics Committee -approved written informed consent
form prior to receiving any study related procedure.

Exclusion Criteria:

1. Patient has radiographic evidence of active (symptomatic, untreated) intraparenchymal
brain metastases; any leptomeningeal metastases; or asymptomatic untreated
intraparenchymal brain metastases requiring treatment.

2. Patient has received more than 1 prior treatment with a non-taxane agent in the
metastatic setting.

3. The only evidence of metastasis is lytic or blastic bone metastases or pleural
effusion or ascites.

4. Patient has a known infection with human immunodeficiency virus or active viral
hepatitis.

5. Patient has active heart disease including myocardial infarction or congestive heart
failure within the previous 6 months, symptomatic coronary artery disease, or
uncontrolled arrhythmias.

6. Any condition which in the Investigator's opinion deems the patient an unsuitable
candidate to receive study drug (e.g., uncontrolled bleeding or bleeding diathesis).

7. Any active infection requiring parenteral or oral antibiotics.

8. The patient receives treatment with any:

- Hormonal or other non-investigational agent therapy within 2 weeks prior to
first dose of study drug;

- Herceptin, mitomycin, or nitrosoureas therapy within 6 weeks prior to first
dose;

- Chemotherapy (except for palliative bisphosphonate therapy for bone pain which
can be administered as clinically indicated) within 4 weeks prior to first dose
study drug;

- Investigational drug or immunotherapy within 4 weeks prior to first dose study
drug;

- Concurrent radiation therapy (except for palliative radiotherapy for

- Radiation therapy within 4 weeks prior to first dose of study drug.

9. Patient has pre-existing peripheral neuropathy of NCI-CTCAE Grade >1.

10. Patient has received paclitaxel, docetaxel, or Abraxane because of metastatic
carcinoma.

11. Known hypersensitivity to paclitaxel, Cremophor EL, or liposomes.

12. Pregnant or nursing female patients.

13. Unwilling or unable to follow protocol requirements.



Age minimum: 18 Years
Age maximum: N/A
Gender: Female
Health Condition(s) or Problem(s) studied
Breast Cancer
Intervention(s)
Drug: LEP-ETU
Primary Outcome(s)
Assessment of Overall Response Rate (ORR) following treatment of LEP-ETU at 275 mg/m2 dose [Time Frame: 2 years]
Secondary Outcome(s)
LEP-ETU 275mg/m2 Induce Progression-Free Survival Assessment [Time Frame: 2 years]
Secondary ID(s)
LEP-ETU 202
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history